FDA reviews new diabetes drugs to assess cancer risk

Recently approved diabetes drugs -- including Merck & Co.'s Januvia and Janumet, Novo Nordisk's Victoza and Bristol-Myers Squibb's Byetta and Bydureon -- are under FDA scrutiny as pancreatic tissue samples in patients who took the medications showed inflammation and cellular changes associated with cancer onset. "FDA has not concluded these drugs may cause or contribute to the development of pancreatic cancer. At this time, patients should continue to take their medicine as directed until they talk to their health care professional," the agency said.

View Full Article in:

Monterey County Herald (Calif.), The · Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care